Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 19 clinical trials
Endocrine Response in Women With Invasive Lobular Breast Cancer

inhibitor therapy. In current clinical practice, patients with invasive lobular carcinoma are treated no differently than patients with invasive ductal carcinoma based on the void of information specific to

ductal carcinoma
lobular carcinoma
ki-67
core needle biopsy
fulvestrant
  • 83 views
  • 05 Feb, 2021
  • 13 locations
Abemaciclib in Treating Patients With Surgically Resectable Chemotherapy Resistant Triple Negative Breast Cancer

This phase II trial studies how well abemaciclib works in treating patients with triple negative breast cancer that can be removed by surgery (resectable) and does not respond to treatment with chemotherapy. Abemaciclib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

total bilirubin
estrogen receptor
fluorouracil
triple negative breast cancer
metastases
  • 6 views
  • 28 Jan, 2021
  • 6 locations
APBI: 27Gy in 5 Fractions for Early Breast Cancer

This study will test the safety of partial breast RT using 27Gy in 5 daily fractions which is expected to be equally tolerated as standard whole breast irradiation (WBI) based on radiobiologic modeling of the fibrosis response of normal tissues but be more convenient and less costly than 3-6 weeks …

carcinoma
breast-conserving surgery
ductal carcinoma
metastasis
female breast cancer
  • 73 views
  • 22 Jan, 2021
  • 1 location
Perioperative Administration of COX 2 Inhibitors and Beta Blockers to Women Undergoing Breast Cancer Surgery

Surgery for breast cancer has a major role in enhancing long term survival and cure, but several physiological aspects associated with surgery are implicated as enhancing tumor spread and formation of distant metastases. These include: an increase in pro-angiogenic factors, direct spread of tumor cells, accumulation of grown factors, immune …

  • 11 views
  • 07 Nov, 2020
  • 2 locations
Genetics of Women With Lobular Carcinoma in Situ of the Breast

RATIONALE: Gathering information about genetic changes in patients with lobular carcinoma in situ of the breast may help doctors learn more about the disease and find better methods of

carcinoma
lobular carcinoma
carcinoma in situ
  • 46 views
  • 07 Nov, 2020
  • 1 location
CDH1 Germline Mutations in Lobular Breast Cancer

Invasive lobular breast carcinoma (ILBC) represents 5-15% of all invasive BCs. The CDH1 gene (OMIM no. 192090), located on the chromosome 16q22.1, encodes for the E-cadherin protein, a key regulator of cell adhesion. Loss of E-cadherin expression is frequently detected in LBC CDH1 germline loss-of-function mutations are associated with the …

  • 2 views
  • 19 Feb, 2021
  • 1 location
11C-Acetate PET/CT Non-FDG-Avid Tumors

F18-FDG is the widely used PET tracer in the routine practice of oncologic disease imaging using the technology of PET-CT. However, FDG-avidity is a characteristic of the individual tumor. There are various types of human malignancies, which are not taking FDG in access. In these cases FDG is not a …

carcinoma
18f-fdg
avid
sarcoma
pet/ct scan
  • 44 views
  • 07 Nov, 2020
  • 1 location
High-Risk Breast Duct Epithelium

/2 or other hereditary genes mutation carriers. Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ. Women

carcinoma
ductal carcinoma
lobular carcinoma
carcinoma in situ
estradiol
  • 8 views
  • 02 Mar, 2021
  • 1 location
Accelerated Partial Irradiation of the Breast: New Altered Fractionation

The aim of this observational study is to evaluate a dose fractionation scheme for APBI using external radiotherapy with modulated intensity technique (IMRT), with the possible impact on the quality of life of patients as it decreases the treatment number of sessions and improves the efficiency and accessibility.

carcinoma
ductal carcinoma
lobular carcinoma
carcinoma in situ
estrogen receptor
  • 0 views
  • 23 Jan, 2021
  • 1 location